Australian Pharmacy Professional Conference and Trade Exhibit 2021
This session will examine the results of a completed clinical study investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers. The bioavailability of Medlab’s cannabis-based medicine has shown superior PK compared to nabiximols (the only cannabis-based medicine approved by the TGA) when used in the management of cancer pain. The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis.
Looking forward to seeing you on Saturday 22 May at 9:15 am.
Date of Event: 2021-05-20